Biontech Se - American Depositary Shares (BNTX) closed at $90.70 on November 4, 2026, up 4.3% from the previous close, on volume of 1,257,229 shares (30-day average 999,349).
Data as of November 4, 2026.
Goldman Sachs Maintains Buy on BioNTech, Keeps $127 Price Target Amid Clinical Catalysts
TipRanks (Thu, 5-Nov 5:15 AM ET)
TipRanks (Thu, 5-Nov 4:20 AM ET)
UBS Keeps Their Buy Rating on BioNTech SE (BNTX)
TipRanks (Wed, 4-Nov 9:05 AM ET)
TipRanks (Wed, 4-Nov 9:00 AM ET)
BioNTech’s Strong Q3 and Oncology Pipeline Support Buy Rating Despite Price Target Cut to $108
TipRanks (Wed, 4-Nov 5:16 AM ET)
TipRanks (Wed, 4-Nov 2:50 AM ET)
Most and least shorted mid- to mega-cap healthcare stocks at the end of October
Seeking Alpha News (Tue, 3-Nov 10:00 AM ET)
BioNTech Reports Third-Quarter Results, Advances Oncology Pipeline
TipRanks (Tue, 3-Nov 9:00 AM ET)
BioNTech Reports Third-Quarter and Nine-Month 2026 Results
TipRanks (Tue, 3-Nov 8:59 AM ET)
Pfizer hikes 2026 outlook despite flat Q3 revenue: names new CFO
Seeking Alpha News (Tue, 3-Nov 7:24 AM ET)
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Biontech Se - American Depositary Shares trades on the NASDAQ stock market under the symbol BNTX.
As of November 5, 2026, BNTX stock price declined to $88.32 with 208,455 million shares trading.
BNTX has a beta of 1.38, meaning it tends to be more sensitive to market movements. BNTX has a correlation of 0.15 to the broad based SPY ETF.
BNTX has a market cap of $22.33 billion. This is considered a Large Cap stock.
Last quarter Biontech Se - American Depositary Shares reported $1 billion in Revenue and $2.03 earnings per share. This beat revenue expectation by $314 million and exceeded earnings estimates by $1.06.
In the last 3 years, BNTX traded as high as $131.49 and as low as $76.53.
The top ETF exchange traded funds that BNTX belongs to (by Net Assets): FBT, IBB, FNDF, IDNA, SPDW.
BNTX has underperformed the market in the last year with a return of -15.7%, while the SPY ETF gained +11.8%. In the last 3 month period, BNTX fell short of the market, returning -3.3%, while SPY returned -2.9%. However, in the most recent 2 weeks BNTX has outperformed the stock market by returning -3.3%, while SPY returned -3.3%.
BNTX support price is $88.42 and resistance is $92.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNTX shares will trade within this expected range on the day.
